Stryker Corporation: EPS $3.52 vs $3.55 expected; revenue $6.52B vs $6.62B
Key Facts
Q3 FY2026 results
| Metric | Actual | Estimate | Surprise | Year ago |
|---|---|---|---|---|
| EPS (USD) | 3.52 | 3.55 | −0.8% | 3.19 |
| Revenue (USD bn) | 6.52 | 6.62 | −1.5% | 6.06 |
Recent reports: actual vs estimate
| Reported | Period | EPS (USD) | Estimate | Surprise | Revenue (USD bn) | Estimate | Surprise |
|---|---|---|---|---|---|---|---|
| Oct 29, 2026 | Q3 FY2026 | 3.52 | 3.55 | −0.8% | 6.52 | 6.62 | −1.5% |
| Jul 30, 2026 | Q2 FY2026 | 3.69 | 3.49 | +5.7% | 6.59 | 6.58 | +0.1% |
| Apr 30, 2026 | Q1 FY2026 | 2.60 | 2.98 | −12.8% | 6.02 | 6.34 | −5.0% |
| Jan 29, 2026 | Q4 FY2025 | 4.47 | 4.40 | +1.6% | 7.17 | 7.12 | +0.7% |
| Oct 30, 2025 | Q3 FY2025 | 3.19 | 3.13 | +1.9% | 6.06 | 6.04 | +0.2% |
| Jul 31, 2025 | Q2 FY2025 | 3.13 | 3.07 | +2.0% | 6.02 | 5.94 | +1.4% |
| May 1, 2025 | Q1 FY2025 | 2.84 | 2.71 | +4.8% | 5.87 | 5.69 | +3.1% |
| Jan 28, 2025 | Q4 FY2024 | 4.01 | 3.87 | +3.6% | 6.44 | 6.36 | +1.2% |
Source: Figures from the EL7 database. Estimates are the analyst consensus carried by our data vendor (FMP), not official figures.
Stryker Corporation results: EPS $3.52 vs $3.55 expected; revenue $6.52B vs $6.62B. The results cover the company's Q3 FY2026. EPS came in below analysts' estimate by 0.8%; revenue below the estimate by 1.5%.
Revenue was up 7.6% from $6.06 billion a year earlier (Q3 FY2025). EPS was up 10.3% from $3.19 a year earlier. On its record, EPS topped analysts' estimates in 6 of 7 earlier comparable reports.
What the results mean
Revenue growth points to an expanding business at Stryker Corporation, but understanding the quality of that growth requires examining product mix and sales profitability. The company combines orthopaedic implants with hospital equipment and supplies, each with distinct demand drivers.
Joint replacement, trauma and spine products are linked to surgical activity and implant use. Surgical equipment, patient handling devices and emergency apparatus are tied to medical facilities’ purchasing decisions, while supplies are linked to daily usage. This diversity makes the distribution of growth across products important to understanding performance.
Neurotechnology and stroke treatment devices add a specialized dimension to the business. Examining their contribution alongside orthopaedics and surgical equipment helps explain the sources of revenue growth and how broadly it extends across operations.
What to watch on the earnings call: Watch management’s explanation of sales growth across implants, equipment, supplies and neurotechnology, and how product mix affects margins. Commentary on demand linked to surgical activity and hospital equipment purchasing will also help clarify the nature and profitability of growth.
For the full analysis of Stryker Corporation stock — valuation, scores and financial statements — see the stock page linked with this story.